Literature DB >> 23681806

Measurement of apo(a) kinetics in human subjects using a microfluidic device with tandem mass spectrometry.

Haihong Zhou1, Jose Castro-Perez, Michael E Lassman, Tiffany Thomas, Wenyu Li, Theresa McLaughlin, Xie Dan, Patricia Jumes, John A Wagner, David E Gutstein, Brian K Hubbard, Daniel J Rader, John S Millar, Henry N Ginsberg, Gissette Reyes-Soffer, Michele Cleary, Stephen F Previs, Thomas P Roddy.   

Abstract

RATIONALE: Apolipoprotein(a) [apo(a)] is the defining protein component of lipoprotein(a) [Lp(a)], an independent risk factor for cardiovascular disease. The regulation of Lp(a) levels in blood is poorly understood in part due to technical challenges in measuring Lp(a) kinetics. Improvements in the ability to readily and reliably measure the kinetics of apo(a) using a stable isotope labeled tracer is expected to facilitate studies of the role of Lp(a) in cardiovascular disease. Since investigators typically determine the isotopic labeling of protein-bound amino acids following acid-catalyzed hydrolysis of a protein of interest [e.g., apo(a)], studies of protein synthesis require extensive protein purification which limits throughput and often requires large sample volumes. We aimed to develop a rapid and efficient method for studying apo(a) kinetics that is suitable for use in studies involving human subjects.
METHODS: Microfluidic device and tandem mass spectrometry were used to quantify the incorporation of [(2)H3]-leucine tracer into protein-derived peptides.
RESULTS: We demonstrated that it is feasible to quantify the incorporation of [(2)H3]-leucine tracer into a proteolytic peptide from the non-kringle repeat region of apo(a) in human subjects. Specific attention was directed toward optimizing the multiple reaction monitoring (MRM) transitions, mass spectrometer settings, and chromatography (i.e., critical parameters that affect the sensitivity and reproducibility of isotopic enrichment measurements). The results demonstrated significant advantages with the use of a microfluidic device technology for studying apo(a) kinetics, including enhanced sensitivity relative to conventional micro-flow chromatography, a virtually drift-free elution profile, and a stable and robust electrospray.
CONCLUSIONS: The technological advances described herein enabled the implementation of a novel method for studying the kinetics of apo(a) in human subjects infused with [(2)H3]-leucine.
Copyright © 2013 John Wiley & Sons, Ltd.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23681806      PMCID: PMC4944116          DOI: 10.1002/rcm.6572

Source DB:  PubMed          Journal:  Rapid Commun Mass Spectrom        ISSN: 0951-4198            Impact factor:   2.419


  26 in total

1.  Quantifying apoprotein synthesis in rodents: coupling LC-MS/MS analyses with the administration of labeled water.

Authors:  Haihong Zhou; Wenyu Li; Sheng-Ping Wang; Vivienne Mendoza; Raymond Rosa; James Hubert; Kithsiri Herath; Theresa McLaughlin; Rory J Rohm; Michael E Lassman; Kenny K Wong; Douglas G Johns; Stephen F Previs; Brian K Hubbard; Thomas P Roddy
Journal:  J Lipid Res       Date:  2012-03-03       Impact factor: 5.922

2.  The metabolism of apolipoproteins (a) and B-100 within plasma lipoprotein (a) in human beings.

Authors:  Jennifer L Jenner; Leo J Seman; John S Millar; Stefania Lamon-Fava; Francine K Welty; Gregory G Dolnikowski; Santica M Marcovina; Alice H Lichtenstein; P Hugh R Barrett; Carl deLuca; Ernst J Schaefer
Journal:  Metabolism       Date:  2005-03       Impact factor: 8.694

3.  Determination of protein replacement rates by deuterated water: validation of underlying assumptions.

Authors:  Emmanuelle Belloto; Frédérique Diraison; Alexandra Basset; Gwenola Allain; Pauline Abdallah; Michel Beylot
Journal:  Am J Physiol Endocrinol Metab       Date:  2007-01-16       Impact factor: 4.310

4.  The metabolism of lipoprotein(a) and other apolipoprotein B-containing lipoproteins: a kinetic study in humans.

Authors:  T Demant; K Seeberg; A Bedynek; D Seidel
Journal:  Atherosclerosis       Date:  2001-08       Impact factor: 5.162

Review 5.  Estimating the fractional synthetic rate of plasma apolipoproteins and lipids from stable isotope data.

Authors:  D M Foster; P H Barrett; G Toffolo; W F Beltz; C Cobelli
Journal:  J Lipid Res       Date:  1993-12       Impact factor: 5.922

6.  Measurement of human plasma proteome dynamics with (2)H(2)O and liquid chromatography tandem mass spectrometry.

Authors:  John C Price; William E Holmes; Kelvin W Li; Nicholas A Floreani; Richard A Neese; Scott M Turner; Marc K Hellerstein
Journal:  Anal Biochem       Date:  2011-09-14       Impact factor: 3.365

7.  Proteome scale turnover analysis in live animals using stable isotope metabolic labeling.

Authors:  Yaoyang Zhang; Stefan Reckow; Christian Webhofer; Michael Boehme; Philipp Gormanns; Wolfgang M Egge-Jacobsen; Christoph W Turck
Journal:  Anal Chem       Date:  2011-02-11       Impact factor: 6.986

8.  Comparison of deuterated leucine, valine, and lysine in the measurement of human apolipoprotein A-I and B-100 kinetics.

Authors:  A H Lichtenstein; J S Cohn; D L Hachey; J S Millar; J M Ordovas; E J Schaefer
Journal:  J Lipid Res       Date:  1990-09       Impact factor: 5.922

9.  A method to determine the kinetics of multiple proteins in human infants with respiratory distress syndrome.

Authors:  Michael S Bereman; Daniela M Tomazela; Hillary S Heins; Manuela Simonato; Paola E Cogo; Aaron Hamvas; Bruce W Patterson; F Sessions Cole; Michael J MacCoss
Journal:  Anal Bioanal Chem       Date:  2012-04-14       Impact factor: 4.142

10.  Heterogeneity of human plasma lipoprotein (a). Isolation and characterization of the lipoprotein subspecies and their apoproteins.

Authors:  G M Fless; C A Rolih; A M Scanu
Journal:  J Biol Chem       Date:  1984-09-25       Impact factor: 5.157

View more
  9 in total

1.  Practical immunoaffinity-enrichment LC-MS for measuring protein kinetics of low-abundance proteins.

Authors:  Michael E Lassman; Thomas McAvoy; Anita Y H Lee; Derek Chappell; Oitak Wong; Haihong Zhou; Gissette Reyes-Soffer; Henry N Ginsberg; John S Millar; Daniel J Rader; David E Gutstein; Omar Laterza
Journal:  Clin Chem       Date:  2014-04-21       Impact factor: 8.327

2.  Static and turnover kinetic measurement of protein biomarkers involved in triglyceride metabolism including apoB48 and apoA5 by LC/MS/MS.

Authors:  Yi Pan; Haihong Zhou; Ablatt Mahsut; Rory J Rohm; Olga Berejnaia; Olga Price; Ying Chen; Jose Castro-Perez; Michael E Lassman; David McLaren; James Conway; Kristian K Jensen; Tiffany Thomas; Gissette Reyes-Soffer; Henry N Ginsberg; David E Gutstein; Michele Cleary; Stephen F Previs; Thomas P Roddy
Journal:  J Lipid Res       Date:  2014-04-02       Impact factor: 5.922

Review 3.  Unbiased and targeted mass spectrometry for the HDL proteome.

Authors:  Sasha A Singh; Masanori Aikawa
Journal:  Curr Opin Lipidol       Date:  2017-02       Impact factor: 4.776

4.  Kinetics of plasma apolipoprotein E isoforms by LC-MS/MS: a pilot study.

Authors:  Valentin Blanchard; Stéphane Ramin-Mangata; Stéphanie Billon-Crossouard; Audrey Aguesse; Manon Durand; Kevin Chemello; Brice Nativel; Laurent Flet; Maud Chétiveaux; David Jacobi; Jean-Marie Bard; Khadija Ouguerram; Gilles Lambert; Michel Krempf; Mikaël Croyal
Journal:  J Lipid Res       Date:  2018-03-14       Impact factor: 5.922

5.  Multiplexed peptide analysis for kinetic measurements of major human apolipoproteins by LC/MS/MS.

Authors:  Mikaël Croyal; Fanta Fall; Véronique Ferchaud-Roucher; Maud Chétiveaux; Yassine Zaïr; Khadija Ouguerram; Michel Krempf; Estelle Nobécourt
Journal:  J Lipid Res       Date:  2016-01-15       Impact factor: 5.922

6.  Effects of mipomersen, an apolipoprotein B100 antisense, on lipoprotein (a) metabolism in healthy subjects.

Authors:  Renu Nandakumar; Anastasiya Matveyenko; Tiffany Thomas; Marianna Pavlyha; Colleen Ngai; Stephen Holleran; Rajasekhar Ramakrishnan; Henry N Ginsberg; Wahida Karmally; Santica M Marcovina; Gissette Reyes-Soffer
Journal:  J Lipid Res       Date:  2018-10-07       Impact factor: 5.922

7.  Personalized Proteomics: The Future of Precision Medicine.

Authors:  Trevor T Duarte; Charles T Spencer
Journal:  Proteomes       Date:  2016-10-01

8.  Effects of PCSK9 Inhibition With Alirocumab on Lipoprotein Metabolism in Healthy Humans.

Authors:  Gissette Reyes-Soffer; Marianna Pavlyha; Colleen Ngai; Tiffany Thomas; Stephen Holleran; Rajasekhar Ramakrishnan; Wahida Karmally; Renu Nandakumar; Nelson Fontanez; Joseph Obunike; Santica M Marcovina; Alice H Lichtenstein; Nirupa R Matthan; James Matta; Magali Maroccia; Frederic Becue; Franck Poitiers; Brian Swanson; Lisa Cowan; William J Sasiela; Howard K Surks; Henry N Ginsberg
Journal:  Circulation       Date:  2016-12-16       Impact factor: 29.690

9.  CETP (Cholesteryl Ester Transfer Protein) Inhibition With Anacetrapib Decreases Production of Lipoprotein(a) in Mildly Hypercholesterolemic Subjects.

Authors:  Tiffany Thomas; Haihong Zhou; Wahida Karmally; Rajasekhar Ramakrishnan; Stephen Holleran; Yang Liu; Patricia Jumes; John A Wagner; Brian Hubbard; Stephen F Previs; Thomas Roddy; Amy O Johnson-Levonas; David E Gutstein; Santica M Marcovina; Daniel J Rader; Henry N Ginsberg; John S Millar; Gissette Reyes-Soffer
Journal:  Arterioscler Thromb Vasc Biol       Date:  2017-07-20       Impact factor: 8.311

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.